Evidence map›Paper›PMID 42376206›Full record

ArticleBlood neoplasia2026

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Eric S Schafer, Holly L Pacenta, Yueh-Yun Chi, Jemily Malvar, Andrew Doan, Reuven J Schore, Teresa Rushing, Roy Leong, Sean Bujarski, Paul S Gaynon and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Eric S SchaferDivision of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine/Dan L. Duncan Cancer Center, Houston, TX.
Holly L PacentaCook Children's Medical Center, Fort Worth, TX.
Yueh-Yun ChiDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Jemily MalvarDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Andrew DoanDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Reuven J SchoreDivision of Pediatric Oncology, Children's National Hospital, Washington, DC.
Teresa RushingDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Roy LeongDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Sean BujarskiDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Paul S GaynonDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Seth E KarolSaint Jude Children's Research Hospital, Memphis, TN.
Julio C BarredoDepartment of Pediatrics and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Susan R RheingoldChildren's Hospital of Philadelphia, Philadelphia, PA.
Van HuynhChildren's Hospital of Orange County, Orange, CA.
Nathan P GossaiChildren's Minnesota, Minneapolis, MN.
Bill H ChangDivision of Hematology and Oncology, Department of Pediatrics, Oregon Health and Science University, Portland, OR.
Tamra SloneDepartment of Pediatrics, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
Melinda PaulyDepartment of Pediatrics, Emory University, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
Alan S WayneDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Deepa BhojwaniDivision of Hematology/Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA.
Terzah M HortonDivision of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine/Dan L. Duncan Cancer Center, Houston, TX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ixazomib (MLN 9708) is an oral proteasome inhibitor, preclinically more potent than bortezomib, that is currently US Food and Drug Administration-approved for the treatment of multiple myeloma. We conducted a phase 1/2 study to estimate the maximum tolerated dose, recommended phase 2 dose (RP2D), and early efficacy of ixazomib when combined with chemotherapy in pediatric patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). Patients aged ≤21 years with R/R ALL/LL (including Down syndrome) were eligible. Ixazomib was combined with up to 3 different 28-day blocks of well-established, relapsed ALL chemotherapy. Ixazomib was tested at 2 dose levels (DL; DL1: 1.6 mg/m

Identifiers

PMID42376206
PMCPMC13312008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.